BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Business

  Castle Biosciences Announces the Appointment of Frank Stokes as Chief Financial Officer

  He joined Castle Biosciences effective December 4, 2017.

  December 7, 2017

   · 

  2 min read
• Drug Development

  BlackThorn Therapeutics Presents Preclinical and Clinical Data From Its First-in-Class NOPR Antagonist at American College of Neuropsychopharmacology Annual Meeting

  Preclinical study results also showed that NOPR antagonism improved motor symptoms in a non-human primate model of Parkinson’s disease.

  December 7, 2017

   · 

  5 min read
• Pharm Country

  AmerisourceBergen Announces Operating Commitments to Address Opioid Diversion and Abuse

  AmerisourceBergen announced today a commitment to a set of ongoing operating principles in order to further support the Company’s efforts to address opioid diversion and abuse.

  December 7, 2017

   · 

  3 min read
• Business

  bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy

  Under the terms of the agreement, bluebird bio and TCB will collaborate to discover and develop CAR-engineered gamma delta T cells for cancer targets and indications.

  December 7, 2017

   · 

  7 min read
• Drug Development

  Vertex Announces Positive Results From Open-Label Phase III Study of KALYDECO (ivacaftor) in Children With Cystic Fibrosis Ages 1 to 2 Years

  The ARRIVAL study met its primary endpoint of safety, showing that ivacaftor was generally well tolerated, and safety data were consistent with those seen in previous Phase 3 studies of ivacaftor in children ages 2 to 5 years and 6 to 11 years.

  December 7, 2017

   · 

  12 min read
• Pharm Country

  Pfizer Announces Private Exchange Offer for Its 6.500 Per Cent

  Pfizer today announced that it has commenced a private offer to exchange (the “Exchange Offer”) any and all of its outstanding £1,500,000,000 6.500 per cent.

  December 7, 2017

   · 

  27 min read
• Drug Development

  Sanofi Explores Combination Treatments for Multiple Myeloma in New Late-Stage Trials

  Both studies will evaluate progression-free survival as the primary endpoint.

  December 7, 2017

   · 

  6 min read
• Business

  China Cord Blood Corporation Announces Results of 2017 Annual General Meeting

  China Cord Blood Corporation today announced the results of its 2017 Annual General Meeting, which was held on December 7, 2017, in Hong Kong S.A.R., China.

  December 7, 2017

   · 

  2 min read
• BioCapital

  The Emmes Corporation Release: New Research Links Umbilical Cord Blood to Motor Function Improvement in Children with Cerebral Palsy

  The research demonstrated improvements in motor function a year after the injection of a high dose of stem cells from a child’s own cord blood.

  December 7, 2017

   · 

  2 min read
• Drug Development

  MeiraGTx Receives Rare Pediatric Disease Designation for A001 for the Treatment of Leber’s Congenital Amaurosis and Treats First Pediatric Patient in Phase I/II Clinical Trial

  The primary endpoint of the study is to determine the safety of the treatment. Secondary endpoints include improvement in visual function including a mobility maze, retinal function, retinal structure and quality of life measures.

  December 7, 2017

   · 

  4 min read